Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Roivant has scheduled an important investor webcast for Wednesday, March 19, 2025, at 8:00 AM ET to discuss important clinical trial results. The presentation will focus on two key areas:
- Results from the Phase 3 study of batoclimab in Myasthenia Gravis (MG)
- Initial findings from the Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The webcast will feature presentations from Pete Salzmann, CEO of Immunovant, and Matt Gline, CEO of Roivant. Investors can register for the event through the company's website, and the presentation will be archived for future viewing under the 'Events & Presentations' section at investor.roivant.com/news-events/events.
Roivant ha programmato un'importante webcast per gli investitori mercoledì 19 marzo 2025, alle 8:00 AM ET, per discutere risultati clinici significativi. La presentazione si concentrerà su due aree chiave:
- Risultati dello studio di Fase 3 di batoclimab nella Miastenia Grave (MG)
- Risultati iniziali dello studio di Fase 2b nella Polineuropatia Demielinizzante Cronica Infiammatoria (CIDP)
La webcast presenterà interventi di Pete Salzmann, CEO di Immunovant, e Matt Gline, CEO di Roivant. Gli investitori possono registrarsi per l'evento tramite il sito web dell'azienda, e la presentazione sarà archiviata per la visione futura nella sezione 'Eventi & Presentazioni' su investor.roivant.com/news-events/events.
Roivant ha programado una importante webcast para inversores el miércoles 19 de marzo de 2025, a las 8:00 AM ET, para discutir resultados clínicos relevantes. La presentación se centrará en dos áreas clave:
- Resultados del estudio de Fase 3 de batoclimab en Miastenia Gravis (MG)
- Hallazgos iniciales del estudio de Fase 2b en Polineuropatía Desmielinizante Crónica Inflamatoria (CIDP)
La webcast contará con presentaciones de Pete Salzmann, CEO de Immunovant, y Matt Gline, CEO de Roivant. Los inversores pueden registrarse para el evento a través del sitio web de la empresa, y la presentación se archivará para su visualización futura en la sección 'Eventos & Presentaciones' en investor.roivant.com/news-events/events.
Roivant는 2025년 3월 19일 수요일 오전 8시(ET)에 중요한 임상 시험 결과를 논의하기 위해 투자자 웹캐스트를 예정하고 있습니다. 발표는 두 가지 주요 분야에 중점을 둘 것입니다:
- 미세근무력증(MG)에 대한 바토클리맙의 3상 연구 결과
- 만성 염증성 탈수초 다발신경병증(CIDP)에 대한 2b상 연구의 초기 발견
웹캐스트에는 Immunovant의 CEO인 Pete Salzmann과 Roivant의 CEO인 Matt Gline의 발표가 포함됩니다. 투자자들은 회사 웹사이트를 통해 이벤트에 등록할 수 있으며, 발표는 investor.roivant.com/news-events/events의 '이벤트 및 발표' 섹션에서 향후 시청을 위해 아카이브됩니다.
Roivant a prévu un important webinaire pour les investisseurs le mercredi 19 mars 2025 à 8h00 ET pour discuter de résultats cliniques importants. La présentation se concentrera sur deux domaines clés :
- Résultats de l'étude de Phase 3 de batoclimab dans la Myasthénie Gravis (MG)
- Premières conclusions de l'étude de Phase 2b dans la Polyneuropathie Inflammatoire Démyelinisante Chronique (CIDP)
Le webinaire comprendra des présentations de Pete Salzmann, PDG d'Immunovant, et de Matt Gline, PDG de Roivant. Les investisseurs peuvent s'inscrire à l'événement via le site Web de l'entreprise, et la présentation sera archivée pour une visualisation future dans la section 'Événements & Présentations' sur investor.roivant.com/news-events/events.
Roivant hat für Mittwoch, den 19. März 2025, um 8:00 Uhr ET ein wichtiges Investor-Webcast geplant, um bedeutende klinische Studienergebnisse zu diskutieren. Die Präsentation wird sich auf zwei zentrale Bereiche konzentrieren:
- Ergebnisse der Phase-3-Studie von Batoclimab bei Myasthenia Gravis (MG)
- Erste Ergebnisse der Phase-2b-Studie bei chronischer entzündlicher demyelinisierender Polyneuropathie (CIDP)
Das Webcast wird Präsentationen von Pete Salzmann, CEO von Immunovant, und Matt Gline, CEO von Roivant, beinhalten. Investoren können sich über die Website des Unternehmens für die Veranstaltung registrieren, und die Präsentation wird für die zukünftige Ansicht im Abschnitt 'Veranstaltungen & Präsentationen' unter investor.roivant.com/news-events/events archiviert.
- None.
- None.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.
Webcast Details
The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
When will Roivant (ROIV) present its batoclimab clinical trial results?
What clinical trial results will be discussed in Roivant's March 19 webcast?
How can investors access Roivant's March 19 clinical trial results webcast?
Which executives will present at Roivant's March 19 clinical trial results webcast?
